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Abstract
SLE pathogenesis is complex, but it is now widely accepted that autoantibodies play a key role in the process by forming
excessive immune complexes; their deposits within tissues leading to inflammation and functional damages. A proliferation
inducing ligand (APRIL) is a member of the tumor necrosis factor (TNF) superfamily mediating antibody-producing plasma
cell (PC)-survival that may be involved in the duration of pathogenic autoantibodies in lupus. We found significant increases
of APRIL at the mRNA and protein levels in bone marrow but not spleen cells from NZB/W lupus mice, as compared to
control mice. Selective antibody-mediated APRIL blockade delays disease development in this model by preventing
proteinuria, kidney lesions, and mortality. Notably, this was achieved by decreasing anti-DNA and anti-chromatin
autoantibody levels, without any perturbation of B- and T- cell homeostasis. Thus, anti-APRIL treatment may constitute an
alternative therapy in SLE highly specific to PCs compared to other B-cell targeting therapies tested in this disease, and likely
to be associated with less adverse effects than any anti-inflammatory and immunosuppressant agents previously used.
Citation: Huard B, Tran NL, Benkhoucha M, Manzin-Lorenzi C, Santiago-Raber M-L (2012) Selective APRIL Blockade Delays Systemic Lupus Erythematosus in
Mouse. PLoS ONE 7(2): e31837. doi:10.1371/journal.pone.0031837
Editor: George C. Tsokos, Beth Israel Deaconess Medical Center, United States of America
Received September 2, 2011; Accepted January 12, 2012; Published February 15, 2012
Copyright:  2012 Huard et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Alliance for Lupus Research, Swiss National Science Foundation, and Leenaards Foundation. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: marie.santiago@unige.ch
Introduction
Systemic Lupus Erythematosus (SLE) is a disorder of systemic
autoimmunity characterized by the production of autoantibodies
and subsequent development of glomerulonephritis (GN). The
availability of several mouse strains, which spontaneously develop
an autoimmune syndrome resembling human SLE, offers the
opportunity to evaluate therapeutic approaches. In human, SLE is
usually treated with steroids in combination with cytotoxic
compounds that targets cycling cells, such as cyclophosphamide.
Although this treatment has been successful in managing SLE, not
all patients respond to cyclophosphamide, implying to explore
alternative treatments [1]. Important efforts are currently being
made to target B cells in this disease (reviewed in [1,2]). Those
treatments include the antagonism of two members of the tumor
necrosis factor (TNF) superfamily, the B-cell activation factor
(BAFF) and a proliferation-inducing ligand (APRIL). BAFF and
APRIL share the transmembrane activator, calcium modulator
and cyclophilin ligand interactor (TACI) and the B-cell maturation
antigen (BCMA) as common receptors from the TNF-R
superfamily [3]. Despite these similarities, BAFF and APRIL are
not redundant molecules. At the receptor level, BAFF binds to
another unique receptor from the TNF-R family, BAFF-R [4],
while APRIL uses heparan sulfate proteoglycans (HSPGs) as co-
receptors [5,6]. Differences were also observed functionally in
genetically deficient animals. BAFF deletion resulted in a profound
decrease in the mature B-cell compartment [7], while APRIL
deletion resulted in a more restricted immune deficiency [8] that
could be attributed to plasma cells (PC) [9].
Two different treatments were first tested pre-clinically to
antagonize BAFF and APRIL. One consists in the use of a soluble
form of TACI, which antagonizes both APRIL and BAFF. The
other one is characterized by a soluble form of BAFF-R, which
antagonizes only BAFF. Both showed promising results in mouse
SLE models with reduction of autoantibody production, decreased
proteinuria and better survival [10,11,12,13,14]. Based on these
results, clinical trials were instigated with soluble TACI and a
monoclonal antibody against human BAFF, in place of soluble
BAFF-R, in SLE patients. Similarly to preclinical experimenta-
tions, these treatments showed interesting results (reviewed in
[1,2]). A BAFF blockade clinically as efficient as BAFF/APRIL
blockade indicates that APRIL antagonism might be dispensable
in SLE. However, APRIL antagonism alone has never been tested
so far, because of the lack of a specific reagent. Here, we report the
generation of the first mAb blocking mouse APRIL and its effect
on lupus spontaneously occurring in NZB/W mice.
Results
Increased level of APRIL production in lupus-prone mice
APRIL polymorphisms have been found to play a role in the
susceptibility to SLE in the Japanese population [15]. In addition,
elevated levels of APRIL in sera or cerebrospinal fluid have been
reported in patients with SLE, which correlated with disease
activity [16,17,18]. In animals such correlation has not been well
investigated so far. For that purpose, we assessed whether lupus
mice expressed elevated levels of APRIL. The abundance of april
mRNA in splenic and bone marrow (BM) cells from 5 mo-old
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NZB females and non-autoimmune female B6 control mice was
quantified by real-time PCR. We found a 2.5- 4.6- and 3.7-fold
increase of april mRNA in BM but not spleen cells (p#0.01) from
NZB, NZW and NZB/W mice, respectively, as compared with
those from B6 females (Figure 1A). We further confirmed APRIL
upregulation by showing an increase of soluble APRIL in
supernatants obtained from BM flushes of NZB/W mice
(Figure 1B).
Characterization of the anti-APRIL blocking antibody
We selected the anti-mouse APRIL IgG1 mAb, Apophe, for its
efficiency (mg/ml range) to block interactions of soluble APRIL
with BCMA and TACI (Figure 2A, B). This inhibition was specific
to APRIL, since Apophe did not modulate the binding of soluble
BAFF to coated BCMA. APRIL binding to a L363 myeloma cell
line was highly dependent on APRIL/HSPG interactions, since it
was completely inhibited by the low molecular weight HSPG,
heparin (Figure 2C). In this assay, Apophe did not inhibit APRIL/
HSPG interactions (Figure 2D). As an in vitro cellular assay, we
monitored APRIL-mediated MHC class II upregulation on B
cells. Figure 2E shows a blockade of MHC class II upregulation in
the presence of Apophe. To test the in vivo activity of Apophe, we
treated female NZB/W mice with 100 mg i.v. of Apophe or control
mouse IgG (cIg) twice a week during 6 weeks starting at 5 months
of age, and studied serum levels of IgA, the antibody isotype the
most affected in APRIL-deficient mice [9]. As shown in figure 2F,
anti-APRIL treated mice showed reduced IgA levels compared to
controls. Taken together, these results show that Apophe
antagonizes mouse APRIL both in vitro and in vivo.
APRIL blockade leads to diminished disease
manifestation in NZB/W mice
We next determined the effect of APRIL blocking on the
development of SLE, in the same groups of NZB/W mice. The
treatment was started at 5 months of age, i.e. before any clinical
sign of kidney diseases, but after the appearance of autoantibodies
in sera. Apophe-treated mice displayed a significant reduction of
proteinuria during the treatment at 6 months of age that persisted
6 weeks after treatment stop, at 7.5 months of age, compared to
isotype-treated mice (means 6 SEM, 6 mo: 0.960.1 vs. 1.460.2,
p,0.05; 7 mo: 1.160.2 vs. 2.160.4, p,0.05) (Figure 3A).
Consistent with the delayed development of proteinuria, only
6% (1/16) of Apophe-treated mice died at 8 months of age, which
contrasted to the higher mortality rate (33%, 6/18) in isotype-
treated mice (p,0.05) (Figure 3B). Apophe-treated mice devel-
oped disease and reached the same mortality rate than isotype-
treated control mice 8 weeks after treatment stop. By 8 months of
age, 3 mice per group were sacrificed, and kidneys were stained for
IgM, IgG and C3 deposits. As depicted in Figure 3C, we observed
less IgM deposits in kidneys from Apophe-treated mice. No clear
difference was observed for IgG and C3. Beneficial effect of
Apophe treatment, compared to untreated or isotype-treated mice,
was also characterized by decreased glomerular cellularity, less
deposits of PAS-positive materials, and no glomerular increased
size.
In vivo APRIL-targeting reduces IgM and IgG
autoantibody production without modulating the
mature T- and B-cell repertoire
We next assessed the immune status of Apophe versus control-
treated mice. Total numbers of spleen and bone marrow cells were
not different in both groups (means 6 SEM, spleen: 246611610
6
in Apophe-treated mice vs. 200621610
6 in isotype-treated
mice, p.0.05; BM: 22.967.4610
6 in Apophe-treated mice vs.
20.861.7610
6 in isotype-treated mice, p.0.05 (N=4 mice per
group)). Analysis of splenic cell populations indicated comparable
frequencies of total B cells, CD4
+ and CD8
+ T cells in control and
Apophe-treated mice (Figure 4A). In addition, we observed no
difference in percentages of B cell precursors in BM from isotype-
and Apophe-treated mice (Figure 4B). We also did not find any
differences in the frequencies of plasmablasts/PC in spleen and
BM. This is consistent with the normal Ig levels, with the
exception of IgA, reported in serum from APRIL
2/2 mice [9], and
the unaltered numbers of plasmablasts/PC we observed in spleen
and BM from (4 month-old) B6.APRIL
2/2 mice in the steady state
situation (means 6 SEM, spleen: 0.6360.07% in APRIL
2/2 vs.
0.6460.02% in WT mice, p.0.05; BM: 0.1660.02% in APRIL
2/2
vs. 0.2860.06% in WT mice, p.0.05 (N=4 mice per group)).
As for IgA, the total IgM levels were reduced at the end of
Apophe treatment compared to pre-treated levels (Figure 5A,
upper panel). Notably, a decrease in IgM autoantibodies against
native DNA (dsDNA) and chromatin compared to cIg-treated
mice (Figure 5A, middle and bottom panels) was observed. In
contrary no effect in the total IgG serum levels was observed
during the 6 weeks period (Figure 5B upper panel). Although
serum levels of IgG anti-dsDNA were not affected (Figure 5B
middle panel), we observed substantial decrease in serum
concentrations of IgG anti-chromatin (means 6 SEM, 7.361.4
vs. 26.369.8 U/ml, p,0.05; Figure 5B bottom panel) in treated
animals. We thus show that in vivo APRIL-targeting leads to
reduction of total IgM, IgM and IgG autoantibodies. The effect on
IgG autoantibodies was dependant on the specificities.
Discussion
APRIL upregulation has been observed in SLE patients. Here,
we show that the increased APRIL level observed in lupus mice
was detectable in the BM, and not in a peripheral lymphoid organ
Figure 1. Increased level of APRIL production in BM from
lupus-prone mice. (A) Levels of APRIL mRNA (means 6 SD, N=3) are
shown in total spleen and BM cells from the indicated mice. (B) Western
blot analysis of APRIL in BM supernatants from the indicated mice.
doi:10.1371/journal.pone.0031837.g001
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myeloid lineage, produce APRIL. In secondary lymphoid organs,
neutrophils, monocytes and dendritic cells are the dominant cells
producing APRIL [19,20], while myeloid precursor cells constitute
an important source of APRIL in BM [21,22,23]. Hence,
increased myelopoiesis in BM may be part of the immune
dysregulation occurring in lupus. Such increased myelopoiesis has
been directly reported in lupus mice [24] or indirectly, by elevated
monocytosis occurring in blood from lupus animals [25,26,27].
With our mAb targeting approach, we are showing for the first
time that APRIL has a role by itself on lupus pathology. Indeed,
APRIL selective blockade for six weeks after disease onset
reduced proteinuria, kidney damages, antibodies levels in the
serum and ameliorated overall mouse survival. Despite the
decreased in antibody levels in serum from Apophe-treated mice,
we did not find any differences in the frequencies of plasma-
blasts/PC in spleen and BM of these mice compared to isotype-
treated mice. This is consistent with the lack of decrease for
plasmablasts/PC in APRIL
2/2 compared to control mice. The
increased survival observed here is very similar to the APRIL/
BAFF antagonism mediated with soluble TACI during treatment
and at early time points after treatment stop (6 weeks) [10,11,12].
Figure 2. Blocking anti-APRIL antibody features. (A) The interaction of APRIL or BAFF with plastic-coated BCMA-Fc was measured in the
presence of the indicated inhibitors by ELISA. (B) The interaction of APRIL with plastic-coated TACI-Fc was measured in the presence of the indicated
inhibitors. CIg (3a1) was irrelevant isotype-matched control for Apophe. (C, D) The binding of APRIL on L363 was measured by flow cytometry, in the
presence of the indicated inhibitors. Ctrl (ACRP30) was irrelevant control for APRIL. Data are representative of three experiments. (E) Total splenocytes
were incubated in medium alone or in the presence of APRIL and the indicated mAbs for 2 days. Mean fluorescence intensity is shown on gated
B220
+ B cells. (F) Serum total IgA levels were evaluated. Each symbol represents an individual animal (six-weeks isotype control- or Apophe-treated
NZB/W 6.5 mo-old female mice). Results are expressed as mg/ml. The mean values are indicated by the horizontal line.
doi:10.1371/journal.pone.0031837.g002
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[10,11,13,14]. Later time points revealed a superiority of the
TACI and BAFF-R over Apophe treatment. This might indicate
that APRIL/BAFF blockade is superior to APRIL blockade. A
conclusion that has some biological sense, even though
pharmacokinetics of TACI-Ig and Apophe has not been
compared. For BAFF-R, it is difficult to draw any conclusion
since the delivery mode, BAFF-R-encoding retrovirus, was
significantly different.
At the Ig level, APRIL blockade reduced IgA and IgM levels. For
IgM, anti-dsDNA and anti-chromatin levels, and for IgG, anti-
chromatin levels were also affected, constituting a molecular
explanation to the disease amelioration observed. Although IgM
autoantibodies have been considered as protective in lupus, total
IgM and/or IgM anti-DNA are used as readout for disease activity
in TACI-Ig or BAFF-R-Ig treated lupus mice experiments, and
their reduction correlates systematically with disease amelioration
[11,14]. Furthermore, our ongoing experiments on CD22-deficient
Figure 3. A blocking anti-APRIL antibody delays disease occurrence in NZB/W mice. (A) The intensity of proteinuria was scored on a 0 to 4
scale. Mean results are shown. (B) 18 isotype control-treated NZB/W (filled circle) and 16 Apophe-treated NZB/W (open circle) female mice were
followed for GN-induced mortality. (C) Representative histological appearance of kidney glomerular lesions from untreated NZB/W, isotype-control
treated and Apophe-treated NZB/W female mice (representative of 3 mice/group). Kidneys sections were stained with either fluorescent anti-IgG,
anti-IgM or anti-C3 mAbs or by PAS for histopathology. Note severe glomerular lesions in untreated and isotype-treated mice, which contrast with
only limited glomerular alterations (focal increases in mesangial cellularity) in Apophe-treated NZB/W mice at 8 months of age (PAS; original
magnification, 6400).
doi:10.1371/journal.pone.0031837.g003
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populations in spleen (A) and BM (B) from treated-mice (N=3 per group) analyzed by flow cytometry at 6 weeks after treatment. Representative flow
cytometry profile for each population is shown. PC, plasma cell and PB, plasmablast. Pro/PreB are expressed as frequency of total B220
+ B cells,
immature and mature B cells as frequency of B220
+ CD43
2 non-precursors B cells.
doi:10.1371/journal.pone.0031837.g004
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production of autoantibodies of IgM class (anti-DNA) rather suggest
a pathogenic role of IgM autoantibodies in lupus.
By contrast, total and anti-dsDNA IgG were unaffected. Hence,
mAb-mediated APRIL blockade largely reproduces the defect
observed in APRIL-deficient mice by affecting mainly IgAs and
IgMs [9]. Previous treatment of NZB/W F1 mice with an
adenovirus secreting soluble TACI resulted in decreased IgM and
IgG anti-dsDNA levels [11,13]. In contrast, soluble BAFF-R
decreased anti-DNA IgG, but had no effect on IgM in this model
[13]. Taken together, this indicates that production of anti-dsDNA
IgM and IgG may be more dependent on APRIL and BAFF,
respectively. These highlight that auto-antibody production in
NZB/W F1 is a complex process, implicating distinct molecular
pathways. Notably, the anti-BAFF and anti-APRIL targeting trial
taught us that it is not necessary to dampen different antibody
subclasses to delay disease occurrence.
It is now clear that lupus pathology can be ameliorated by
several B-cell targeting therapies, at least in the NZB/W mouse
spontaneous model. While others have reported disease amelio-
ration by affecting the mature B-cell repertoire without altering the
autoantibody levels [10], we are showing here the opposite.
Indeed, we obtained a similar delay in lupus occurrence, by
reducing autoantibodies without affecting the host mature B-cell
repertoire, as expected from the immune phenotype of APRIL-
deficient mice. Hence, PC targeting by APRIL antagonism
constitutes a novel attractive therapy for SLE patients. Future
clinical trials should tell us whether mature B-cell or plasma-cell
targeting is the best effective treatment with minimal adverse
immunosuppressive effects.
Figure 5. A blocking anti-APRIL antibody decreases autoantibody serum levels. (A, B) Each symbol represents an individual animal (18
isotype-treated control NZB/W (cIg) and 16 Apophe-treated NZB/W female mice, before (5 mo.) and after treatment (6.5 mo.). Results are expressed
as mg/ml for total IgM and IgG and as U/ml for anti-dsDNA and anti-chromatin autoantibodies. The mean values are indicated by the horizontal bar.
doi:10.1371/journal.pone.0031837.g005
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Ethics statement
Animal experiments described in the present study have been
approved by the Geneva ethics committee veterinarian office
(protocol ID number: 1005/3536/3).
Mice
Female NZB, male NZW and female NZB/W mice were
purchased at the Jackson Laboratory. Female C57BL/6J (B6) mice
were obtained from local breeding. B6.APRIL
2/2 mice were
kindly provided by Dr Ashkenazi (Genentech). Proteinuria was
tested in urine by Albustix reagent strips (Siemens Healthcare
Diagnostics Inc.) every other week, and scored on a scale from 0 to
4 according to protein concentration (from 0 to $20 g/l).
Anti-APRIL generation, production, and characterization
The IgG1 Apophe mAb was generated by immunizing
B6.APRIL
2/2 mice subcutaneously with murine recombinant
APRIL (Adipogen) in Stimune adjuvant (Prionics), and fusion of
primed leukocytes from draining inguinal lymph nodes with the
X63Ag8 myeloma cell line (American tissue culture collection,
ATCC). The antagonism activity of Apophe for APRIL/BCMA
or TACI interaction was tested in a standard ELISA assay. Briefly,
huTACI-Ig or huBCMA-Ig (Adipogen, 1 mg/ml) were coated o/n
at 4uC. Plates were blocked and the binding of flag-tagged
muAPRIL fused to ACRP30 (APRIL/ACRP30, Adipogen,
300 ng/ml) or flag-tagged muBAFF (Adipogen, 300 ng/ml) was
revealed with a biotinylated anti-flag (clone M2, Sigma) followed
by steptavidin-conjugated horseradish peroxidasae (BD Bioscienc-
es). The antagonism activity of Apophe for APRIL/HSPG
interaction was tested by flow cytometry with the myeloma L363
cell line (ATCC). Briefly, 1 mg/ml flag-tagged murine APRIL/
ACRP30 or control ACRP30 (Adipogen) was incubated with L363
cells, and binding was revealed with biotinylated anti-flag,
followed by steptavidin-conjugated phycoerythrin (BD Bioscienc-
es). Control Ig (cIg) was an IgG1 anti-huCD7 (clone 3a1, ATCC).
Both mAbs were produced in serum-free medium and purified on
protein-G sepharose. Absence of endotoxin contamination in
purified mAb preparation was tested in a LAL assay (Lonza). For
the MHC-class II upregulation test, total splenocytes were
incubated with 1 mg/ml of murine APRIL (Adipogen) as
previously reported [28]. After two days, MHC class II expression
was monitored by flow cytometry on gated B220
+ B cells with the
mAb AF6-120.1 (BD pharmingen).
Quantitative RT-PCR
RNAs from BM and spleen cells were prepared with TRIzol
reagent (Invitrogen AG). APRIL mRNA was quantified by real-
time RT-PCR with cDNA prepared from RNA. cDNA was
amplified using the following primers: forward primer 59-
CTGGAGGCCAGGGAGACAT-39 and reverse primer 59-
GCACGGTCAGGATCAGAAGG-39. PCR was performed using
the iCycler iQ Real-Time PCR Detection System (Bio-Rad) and
iQ SYBR green Supermix (Bio-Rad). Results were quantified
relative to a standard curve generated with serial dilutions of a
reference cDNA preparation from spleen and normalized using
TATA-binding protein (TBP) mRNA.
Western blot analysis
Supernatant of BM flushes, obtained after centrifugation of
whole tibiae and femurs in a fixed volume (100 ml) of PBS, were
loaded onto 15% SDS-PAGE gel (20 mg protein per lane), and
transferred to nitrocellulose membrane (Bio-Rad) with a semi-dry
blotting apparatus (Bio-Rad). After blocking o/n at RT in 20 mM
Tris-HCl (pH 7.4), 150 mM NaCl, and 0.1% Tween 20
containing 1% non-fat dry milk powder, membranes were
incubated with the ED2 rabbit polyclonal anti-APRIL antibody
(4 mg/ml) (ProSci) 1h30 at RT. Thoroughly washed membranes
were incubated with HRP-conjugated goat anti-rabbit IgG (Bio-
Rad) for 1 h at RT. Chemiluminescence development was
conducted with the Amersham-ECL reagents (GE Healthcare
Biosciences), and the membranes were exposed to HyperFilm
ECL (GE Healthcare Biosciences).
Histology
Kidney samples were collected when mice were sacrificed either
at 8 months-old or at the end of the experiment. For
immunofluorescence staining, kidneys were embedded in Tissue-
Tek O.C.T. compound (Miles) and snap-frozen in liquid nitrogen.
Four mm frozen sections were stained with Alexa Fluor 488-
labelled anti-mouse IgG (Invitrogen), TXRD-labeled anti-mouse
IgM (Southern Biotechnology) and FITC-labeled anti-mouse C3
(Cappel) antibodies in the presence of 2.4G2 anti-FccRII/III
mAb. For histopathology, sections were stained with periodic acid-
Schiff (PAS) reagent. The extent of glomerulonephritis was based
on the intensity and extent of histopathological changes, as
described previously [29].
Flow cytometric analysis
Flow cytometry was performed using three- or four-color
staining and analyzed with a FACSCalibur (BD Biosciences). The
following antibodies were used: anti-B220 (RA3-6B2), anti-CD4
(GK1.5), anti-CD8 (53-6.7), anti-CD138 (281-2), anti-CD43 (S7)
(e-biosciences), anti- IgM (lomm9), and anti-IgDa (AMS15.1).
Staining was performed in the presence of saturating concentra-
tion of 2.4G2 anti-Fc-RII/III mAb.
Serological analysis
Serum levels of IgG autoantibodies against chromatin and
dsDNA were determined by ELISA. Chromatin, prepared from
chick erythrocytes was directly coated to ELISA plates, whereas
calf-thymus dsDNA was coated to ELISA plates precoated with
poly-L-lysine (Sigma-Aldrich). Plates were then incubated with 1/
100 diluted serum samples, and development performed with
alkaline phosphatase-labeled goat anti-mouse IgM or IgG. For
anti-dsDNA and anti-chromatin antibodies, results are expressed
in U/ml in reference to a standard curve obtained with a serum
pool of MRL-Fas
lpr mice. Serum levels of total IgA, IgG and IgM
were quantified by ELISA and results are expressed in mg/ml or
mg/ml by referring to a standard curve obtained with a mouse
serum with known IgA, IgG and IgM concentrations (Miles
Laboratories).
Statistical analysis
The Kaplan-Meyer log-rank test was used for the statistical
analysis of mortality rates. Analysis of serological parameters was
performed by the Mann-Whitney U-test. Unpaired comparisons
for mRNA expression and proteinuria levels were carried out by
the Student’s t test. Probability values ,5% were considered
significant.
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